Amifostine ameliorates bleomycin-induced murine pulmonary fibrosis via NAD⁺/SIRT1/AMPK pathway-mediated effects on mitochondrial function and cellular metabolism.

ABSTRACT:

Background

Idiopathic pulmonary fibrosis (IPF) is a devastating chronic lung disease characterized by irreversible scarring of the lung parenchyma. Despite various interventions aimed at mitigating several different molecular aspects of the disease, only two drugs with limited clinical efficacy have so far been approved for IPF therapy.

Objective

We investigated the therapeutic efficacy of amifostine, a detoxifying drug clinically used for radiation-caused cytotoxicity, in bleomycin-induced murine pulmonary fibrosis.

Methods

C57BL6/J mice were intratracheally instilled with 3 U/kg of bleomycin. Three doses of amifostine (WR-2721, 200 mg/kg) were administered intraperitoneally on days 1, 3, and 5 after the bleomycin challenge. Bronchoalveolar lavage fluid (BALF) was co

SUBMITTER: Guo F 

PROVIDER: S-EPMC10799491 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature